During the 62nd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Ali Bazarbachi, American University of Beirut, Beirut, LB, about the new advances for treating acute GvHD.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
What is new for treating acute GvHD?
What is new for treating acute GvHD?
In this video, Bazarbachi discusses the results of a study evaluating the fecal microbiota transfer product MaaT013, a pooled-donor, full-ecosystem microbiota biotherapeutic, for the treatment of 29 patients with intestinal acute GvHD as part of a compassionate use/expanded access treatment program.
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox